Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.2 EUR | +3.85% | +5.17% | +38.86% |
05-07 | AstraZeneca target raised; Antofagasta lowered | AN |
04-18 | Defense stocks weak - JPM: Use correction at Rheinmetall | DP |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Aerospace & Defense
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+38.86% | 3.33B | - | ||
+23.53% | 137B | C | ||
+12.74% | 80.36B | B | ||
+0.74% | 70.11B | A- | ||
+24.40% | 51.87B | B | ||
+43.04% | 43.89B | A- | ||
+2.46% | 40.95B | B+ | ||
+37.54% | 29.77B | C- | ||
+86.34% | 24.75B | B | ||
+20.72% | 23.6B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BAB Stock
- BW3 Stock
- Ratings Babcock International Group PLC